EZN-2208 (PEG-SN38), A 40 kDa polyethylene glycol (PEG) conjugate, as an anticancer agent: Review of preclinical and clinical data

Current Bioactive Compounds

Volumn 7, Issue 1, 2011, Pages 3-7

  Zhao, Hong ^a  

^a Enzon Incorporated   (United States)

Author keywords

Cancer; EZN 2208; PEG conjugate; PEG SN38; Prodrug; Topoisomerase I

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; EZN 2208; GRANULOCYTE COLONY STIMULATING FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRINOTECAN; MACROGOL; PRODRUG; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BURKITT LYMPHOMA; CANCER INHIBITION; COLORECTAL CANCER; CYTOTOXICITY; DIARRHEA; DRUG CONJUGATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

EID: 79953888514     PISSN: 15734072     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340711795163802     Document Type: Review

References (22)

1. Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer, 2006, 6, 789-802.
2. Chabot, G.G. Clinical pharmacokinetics of irinotecan. Clin. Pharmacokinet., 1997, 33, 245-259.
3. Slatter, J.G., Schaaf, L.J., Sams, J.P., Feenstra, K.L., Johnson, M.G., Bombardt, P.A., Cathcart, K.S., Verburg, M.T., Pearson, L.K., Compton, L.D., Miller, L.L., Baker, D.S., Pesheck, C.V., Lord 3rd, R.S. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [14C]CPT-11 in cancer patients. Drug Metab. Dispos., 2000, 28, 423-433.
4. Guichard, S.M., Danks, M.K. Topoisomerase enzymes as drug targets. Curr. Opin. Oncol., 1999, 11, 482-489.
5. Mathijssen, R.H.J., van Alphen, R.J., Verweij, J., Loos, W.J., Nooter, K., Stoter, G., Sparreboom, A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res., 2001, 7, 2182-2194.
6. Smith, N.F., Figg, W.D., Sparreboom, A. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol. In Vitro, 2006, 20, 163-175.
7. Krishnamurthy, P., Schuetz, J.D. Role of ABCG2/BCRP in biology and medicine. Annu. Rev. Pharmacol. Toxicol., 2006, 46, 381-410.
8. Zhang, J.A., Xuan, T., Parmar, M., Ma, L., Ugwu, S., Ali, S., Ahmad, I. Development and characterization of a novel liposomebased formulation of SN-38. Int. J. Pharm., 2004, 270, 93-107.
9. Greenwald, R.B., Zhao, H. Poly (ethylene glycol) prodrugs: altered pharmacokinetics and pharmacodynamics. In: Prodrugs: Challenges and Rewards; Part 1; Stella, V.J., Borchardt, R.T., Hageman, M.J., Oliyai, R., Maag, H., Tilley, J.W., Eds. Springer: New York, 2007, Chapter 2.3.1, pp. 283-338.
10. Greenwald, R.B., Choe, Y.H., McGuire, J., Conover, C.D. Effective drug delivery by PEGylated drug conjugates. Adv. Drug Deliv. Rev., 2003, 55, 217-250.
11. Greenwald, R. B., Pendri, A., Conover, C., Gilbert, C., Yang, R., Xia, J. Drug delivery systems. 2. Camptothecin 20-O-poly(ethylene glycol) ester transport forms. J. Med. Chem., 1996, 39, 1938-1940.
12. Zhao, H., Lee, C., Sai, P., Choe, Y.H., Boro, M., Pendri, A., Guan, S., Greenwald, R.B. 20-O-acylcamptothecin derivatives: evidence for lactone stabilization. J. Org. Chem., 2000, 65, 4601-4606.
13. Zhao, H., Rubio, B., Sapra, P., Wu, D., Reddy, P., Sai, P., Martinez, A., Gao, Y., Lozanguiez, Y., Longley, C., Greenberger, L.M., Horak, I.D. Novel prodrugs of SN38 using multi-arm poly(ethylene glycol) linkers. Bioconjug. Chem., 2008, 19, 849-859.
14. Sapra, P., Zhao, H., Mehlig, M., Malaby, J., Kraft, P., Longley, C., Greenberger, L.M., Horak, I.D. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including camptothecin-11ii refractory model. Clin. Cancer Res., 2008, 14, 1888-1896.
15. Sapra, P., Kraft, P., Mehlig, M., Malaby, J., Zhao, H., Greenberger, L.M., Horak, I.D. Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma. Haematologica, 2009, 94, 1456-1459.
16. Pastorino, F., Loi, M., Cilli, M., Emionite, L., Zhao, H., Sapra, P., Greenberger, L.M., Ribatti, D., Daga, A., Ponzoni, M. EZN-2208, a novel PEGylated SN-38 drug conjugate, markedly inhibits tumor growth and metastatic spreading in preclinical models of human neuroblastoma. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research (AACR); Denver, CO: Philadelphia (PA): April 18-22, 2009, Abstract 1699.
17. Maeda, H., Wu, J., Sawa, T., Matsumura, Y., Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release, 2000, 65, 271-284.
18. Sapra, P., Kraft, P., Mehlig, M., Malaby, J., Castaneda, S., Greenberger, L.M., Horak, I.D. A novel polyethyleneglycol-SN38 conjugate, EZN-2208, down-regulates HIF-1α and results in significant tumor growth inhibition in K-ras mutant cancer xenograft models. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research (AACR); Denver, CO: Philadelphia (PA): April 18-22, 2009, Abstract LB-39.
19. Semenza, G.L. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today, 2007, 12, 853-859.
20. Rapisarda, A., Uranchimeg, B., Sordet, O., Pommier, Y., Shoemaker, R.H., Melillo, G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res., 2004, 64, 1475-1482.
21. Kurzrock, R., Wheler, J., Hong, D.S., Guo, Z., Mulcahy, M.F., Benson III, A.B., Goel, S., Swami, U., Mani, S., Buchbinder, A. Phase 1, first-in-human, dose-escalation study of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies. Mol. Cancer Ther., 2009, 8, Abstract C216.
22. Patnaik, A., Papadopoulos, K.P., Beeram, M., Kee, D., Tolcher, A.W., Schaaf, L.J., Tahiri, S., Bekaii-Saab, T., Buchbinder, A. EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies: a Phase 1 dose-escalation study. Mol. Cancer Ther., 2009, 8, Abstract C221.